Resources

30-year study shows effects of breastfeeding on diabetes incidence in women of child-bearing age.

GLP-1 agonists randomized showdown. Which agent is better?

Evaluating if bolus calculators for insulin pumps can be accurately calibrated by speech recognition.

A study examining the timing of foods and its associated risk to islet autoimmunity.

How does cost play in your determination for treatment? Follow the link to see how you and your colleagues compare.

A 68-year-old male presents to your office for a follow-up visit. His past medical history is significant for a myocardial infarction (five years ago) and he has type 2 diabetes. His current medications include an ACE inhibitor, a statin, aspirin, and metformin. Despite good compliance with his medications and beneficial lifestyle changes, he is not able to achieve his individualized target A1C of 7.5-8%. You decide it would be beneficial to add a second antihyperglycemic agent. Which of the following medications should be avoided due to CVD risk? A.Pioglitazone B. Exenatide C. Rosiglitazone D. Sitaglipitin E. None of the above Follow the link for the answer.

Dr. Ronald S. Swerdloff graduated with his BS from UCLA/UCB in 1959 and an MDvin 1962 from UCSF. He began his clinical training at the University of Washington, only to be drafted and expected to serve as a medical officer in the Vietnam war. Instead he was assigned to a brilliant physician scientist at the NIH and finally finished his training back at UCLA. Dr. Swerdloff has been a leader in reproductive endocrinology for the last four decades, including pubertal development, male contraception, androgen physiology and modeling, androgen drug development and hormones in aging.

In this Exclusive Interview transcript, Dr. Ronald Swerdloff discusses his work on male hypogonadism and diabetes, low testosterone treatments, and the impact of such treatment on cancer.

In this Exclusive Interview, Dr. Ronald Swerdloff talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about male hypogonadism, low testosterone treatements, and the impact of such treatment on cancer.

In part 1 of this Exclusive Interview, Dr. Ronald Swerdloff explains male hypogonadism in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.